Literature DB >> 11095581

Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

D M Stresser1, A P Blanchard, S D Turner, J C Erve, A A Dandeneau, V P Miller, C L Crespi.   

Abstract

Inhibition of cytochrome P450 catalytic activity is a principal mechanism for pharmacokinetic drug-drug interactions. Rapid, in vitro testing for cytochrome P450 inhibition potential is part of the current paradigm for identifying drug candidates likely to give such interactions. We have explored the extent that qualitative and quantitative inhibition parameters are dependent on the cytochrome P450 (CYP) 3A4 probe substrate. Inhibition potential (e.g., IC(50) values from 8-point inhibition curves) or activation potential for most compounds varied dramatically depending on the fluorometric probe substrates for CYP3A4 [benzyloxyresorufin (BzRes), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ), and dibenzylfluorescein (DBF)]. For 21 compounds that were primarily inhibitors, the range of IC(50) values for the four substrates varied from 2.1- to 195-fold with an average of 29-fold. While the rank order of sensitivity among the fluorometric substrates varied among the individual inhibitors, on average, BFC dealkylation was the most sensitive to inhibition, while BQ dealkylation was least sensitive. Partial inhibition was observed with BzRes and BQ but not for BFC and DBF. BzRes was more prone to activation, whereas dramatic changes in IC(50) values were observed when the BQ concentration was below the S(50). Three different correlation analyses indicated that IC(50) values with BFC, BQ, and DBF correlated well with each other, whereas the response with BzRes correlated more weakly with the other substrates. One of these correlation analyses was extended to the percent inhibition of 10 microM inhibitor with the standard CYP3A4 probe substrates testosterone, midazolam, and nifedipine. In this analysis the responses with BQ, BFC and DBF correlated well with testosterone and midazolam but more poorly with nifedipine. In the aggregate, BFC and DBF appear more suitable as an initial screen for CYP3A4 inhibition. However, the substrate-dependent effects reported here and by others indicate that all CYP3A4 inhibition data should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095581

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Authors:  Zongling Xia; Mingli Wang; Sulan Zou; Rong Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 2.441

2.  High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates.

Authors:  Bryan D Marks; Tony A Goossens; Heidi A Braun; Mary S Ozers; Ronald W Smith; Connie Lebakken; Olga V Trubetskoy
Journal:  AAPS PharmSci       Date:  2003

3.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

4.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Authors:  Daniel R McMasters; Rhonda A Torres; Susan J Crathern; Deborah L Dooney; Robert B Nachbar; Robert P Sheridan; Kenneth R Korzekwa
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

5.  The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.

Authors:  Motohiro Kato; Yoshihisa Shitara; Hitoshi Sato; Kunihiro Yoshisue; Masaru Hirano; Toshihiko Ikeda; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-05-16       Impact factor: 4.200

6.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 7.  Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Authors:  Sandhya Devarajan; Irene Moon; Ming-Fen Ho; Nicholas B Larson; Drew R Neavin; Ann M Moyer; John L Black; Suzette J Bielinski; Steven E Scherer; Liewei Wang; Richard M Weinshilboum; Joel M Reid
Journal:  Drug Metab Dispos       Date:  2019-02-11       Impact factor: 3.922

9.  Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.

Authors:  Shyam H Kamble; Abhisheak Sharma; Tamara I King; Erin C Berthold; Francisco León; P Katharina L Meyer; Siva Rama Raju Kanumuri; Lance R McMahon; Christopher R McCurdy; Bonnie A Avery
Journal:  Toxicol Lett       Date:  2019-11-07       Impact factor: 4.372

10.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.